249 related articles for article (PubMed ID: 34075699)
1. MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary.
Laprovitera N; Riefolo M; Porcellini E; Durante G; Garajova I; Vasuri F; Aigelsreiter A; Dandachi N; Benvenuto G; Agostinis F; Sabbioni S; Berindan Neagoe I; Romualdi C; Ardizzoni A; Trerè D; Pichler M; D'Errico A; Ferracin M
Mol Oncol; 2021 Oct; 15(10):2732-2751. PubMed ID: 34075699
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin.
Ferracin M; Pedriali M; Veronese A; Zagatti B; Gafà R; Magri E; Lunardi M; Munerato G; Querzoli G; Maestri I; Ulazzi L; Nenci I; Croce CM; Lanza G; Querzoli P; Negrini M
J Pathol; 2011 Sep; 225(1):43-53. PubMed ID: 21630269
[TBL] [Abstract][Full Text] [Related]
3. Efficient identification of miRNAs for classification of tumor origin.
Søkilde R; Vincent M; Møller AK; Hansen A; Høiby PE; Blondal T; Nielsen BS; Daugaard G; Møller S; Litman T
J Mol Diagn; 2014 Jan; 16(1):106-15. PubMed ID: 24211363
[TBL] [Abstract][Full Text] [Related]
4. Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin.
Rosenwald S; Gilad S; Benjamin S; Lebanony D; Dromi N; Faerman A; Benjamin H; Tamir R; Ezagouri M; Goren E; Barshack I; Nass D; Tobar A; Feinmesser M; Rosenfeld N; Leizerman I; Ashkenazi K; Spector Y; Chajut A; Aharonov R
Mod Pathol; 2010 Jun; 23(6):814-23. PubMed ID: 20348879
[TBL] [Abstract][Full Text] [Related]
5. A second-generation microRNA-based assay for diagnosing tumor tissue origin.
Meiri E; Mueller WC; Rosenwald S; Zepeniuk M; Klinke E; Edmonston TB; Werner M; Lass U; Barshack I; Feinmesser M; Huszar M; Fogt F; Ashkenazi K; Sanden M; Goren E; Dromi N; Zion O; Burnstein I; Chajut A; Spector Y; Aharonov R
Oncologist; 2012; 17(6):801-12. PubMed ID: 22618571
[TBL] [Abstract][Full Text] [Related]
6. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary.
Varadhachary GR; Spector Y; Abbruzzese JL; Rosenwald S; Wang H; Aharonov R; Carlson HR; Cohen D; Karanth S; Macinskas J; Lenzi R; Chajut A; Edmonston TB; Raber MN
Clin Cancer Res; 2011 Jun; 17(12):4063-70. PubMed ID: 21531815
[TBL] [Abstract][Full Text] [Related]
7. A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.
Posner A; Prall OW; Sivakumaran T; Etemadamoghadam D; Thio N; Pattison A; Balachander S; Fisher K; Webb S; Wood C; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Wright G; Williams S; George J; Hicks RJ; Boussioutas A; Gill AJ; Solomon BJ; Xu H; Fellowes A; Fox SB; Schofield P; Bowtell D; Mileshkin L; Tothill RW
J Pathol; 2023 Jan; 259(1):81-92. PubMed ID: 36287571
[TBL] [Abstract][Full Text] [Related]
8. Accurate classification of metastatic brain tumors using a novel microRNA-based test.
Mueller WC; Spector Y; Edmonston TB; St Cyr B; Jaeger D; Lass U; Aharonov R; Rosenwald S; Chajut A
Oncologist; 2011; 16(2):165-74. PubMed ID: 21273512
[TBL] [Abstract][Full Text] [Related]
9. Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin.
Saller JJ; Haider M; Al-Diffalha S; Coppola D
Anticancer Res; 2022 Mar; 42(3):1381-1396. PubMed ID: 35220231
[TBL] [Abstract][Full Text] [Related]
10. Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors.
Pentheroudakis G; Spector Y; Krikelis D; Kotoula V; Meiri E; Malamou-Mitsi V; Fountzilas G; Sanden M; Pavlidis N; Benjamin H; Aharonov R
Clin Exp Metastasis; 2013 Apr; 30(4):431-9. PubMed ID: 23124598
[TBL] [Abstract][Full Text] [Related]
11. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
[TBL] [Abstract][Full Text] [Related]
12. Cancers of unknown primary origin (CUP) are characterized by chromosomal instability (CIN) compared to metastasis of know origin.
Vikeså J; Møller AK; Kaczkowski B; Borup R; Winther O; Henao R; Krogh A; Perell K; Jensen F; Daugaard G; Nielsen FC
BMC Cancer; 2015 Mar; 15():151. PubMed ID: 25885340
[TBL] [Abstract][Full Text] [Related]
13. A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary.
Chen K; Zhang F; Yu X; Huang Z; Gong L; Xu Y; Li H; Yu S; Fan Y
J Transl Med; 2022 Apr; 20(1):158. PubMed ID: 35382836
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases.
Heinzelmann J; Unrein A; Wickmann U; Baumgart S; Stapf M; Szendroi A; Grimm MO; Gajda MR; Wunderlich H; Junker K
Ann Surg Oncol; 2014 Mar; 21(3):1046-54. PubMed ID: 24242678
[TBL] [Abstract][Full Text] [Related]
15. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence.
Zhao Y; Pan Z; Namburi S; Pattison A; Posner A; Balachander S; Paisie CA; Reddi HV; Rueter J; Gill AJ; Fox S; Raghav KPS; Flynn WF; Tothill RW; Li S; Karuturi RKM; George J
EBioMedicine; 2020 Nov; 61():103030. PubMed ID: 33039710
[TBL] [Abstract][Full Text] [Related]
16. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin.
Tothill RW; Kowalczyk A; Rischin D; Bousioutas A; Haviv I; van Laar RK; Waring PM; Zalcberg J; Ward R; Biankin AV; Sutherland RL; Henshall SM; Fong K; Pollack JR; Bowtell DD; Holloway AJ
Cancer Res; 2005 May; 65(10):4031-40. PubMed ID: 15899792
[TBL] [Abstract][Full Text] [Related]
17. A Review on Cancer of Unknown Primary Origin: The Role of Molecular Biomarkers in the Identification of Unknown Primary Origin.
Yan N; Zhang Y; Guo X; Yuan D; Tian G; Yang J
Methods Mol Biol; 2020; 2204():109-119. PubMed ID: 32710319
[TBL] [Abstract][Full Text] [Related]
18. Overview of various techniques/platforms with critical evaluation of each.
Agwa E; Ma PC
Curr Treat Options Oncol; 2013 Dec; 14(4):623-33. PubMed ID: 24243164
[TBL] [Abstract][Full Text] [Related]
19. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
Varadhachary GR; Talantov D; Raber MN; Meng C; Hess KR; Jatkoe T; Lenzi R; Spigel DR; Wang Y; Greco FA; Abbruzzese JL; Hainsworth JD
J Clin Oncol; 2008 Sep; 26(27):4442-8. PubMed ID: 18802157
[TBL] [Abstract][Full Text] [Related]
20. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
Dermawan JK; Rubin BP
Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
